Leukemia M3 refers to acute promyelocytic leukemia, which is usually treated for a longer period of time, but does not usually require lifelong medication. If the disease is in remission, the PML-RARA fusion gene is monitored as negative after maintenance treatment, and the blood count is normalized, the drug can be discontinued. However, regular checkups should be conducted to observe the relapse of the disease, and in case of relapse, treatment should be induced again in a timely manner, and bone marrow transplantation may be required for repeated relapses. Leukemia M3 has a pronounced tendency to bleed and has an aggressive onset, which may lead to early death, and can be cured mainly by treatment such as induction of differentiation or chemotherapy. The overall course of treatment for leukemia M3 is generally about 18 months, otherwise the disease may relapse. For example, low-risk patients may choose vincristine and erythromycin for consolidation therapy. During maintenance treatment, liver and kidney functions need to be reviewed regularly and should not be discontinued prematurely to avoid affecting the therapeutic effect. If there is a significant decrease in neutrophils, infectious comorbidities, or adverse drug reactions such as chest tightness or rash, discontinuation of the drug is recommended if necessary.